Brunel University Research Archive (BURA) >
University >
Publications >

Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/7016

Title: Cost-effectiveness of a European preventive cardiology programme in primary care: A Markov modelling approach
Authors: Mistry, H
Morris, S
Kotseva, K
Wood, D
Buxton, MJ
Publication Date: 2012
Publisher: BMJ Publishing Group
Citation: BMJ Open, 2(5): e001029, Oct 2012
Abstract: OBJECTIVE: To investigate the longer-term cost-effectiveness of a nurse-coordinated preventive cardiology programme for primary prevention of cardiovascular disease (CVD) compared to routine practice from a health service perspective. DESIGN: A matched, paired cluster-randomised controlled trial. SETTING: Six pairs of general practices in six countries. PARTICIPANTS: 1019 patients were randomised to the EUROACTION intervention programme and 1005 patients to usual care (UC) and who completed the 1-year follow-up. OUTCOME MEASURES: Evidence on health outcomes and costs was based on patient-level data from the study, which had a 1-year follow-up period. Future risk of CVD events was modelled, using published risk models based on patient characteristics. An individual-level Markov model for each patient was used to extrapolate beyond the end of the trial, which was populated with data from published sources. We used an 11-year time horizon and investigated the impact on the cost-effectiveness of varying the duration of the effect of the intervention beyond the end of the trial. Results are expressed as incremental cost per quality-adjusted life-year gained. RESULTS: Unadjusted results found the intervention to be more costly and also more effective than UC. However, after adjusting for differences in age, gender, country and baseline risk factors, the intervention was dominated by UC, but this analysis was not able to take into account the lifestyle changes in terms of diet and physical activity. CONCLUSIONS: Although the EUROACTION study achieved healthier lifestyle changes and improvements in management of blood pressure and lipids for patients at high risk of CVD, compared to UC, it was not possible to show, using available risk equations which do not incorporate diet and physical activity, that the intervention reduced longer-term cardiovascular risk cost-effectively. Whether or not an intervention such as that offered by EUROACTION is cost-effective requires a longer-term trial with major cardiovascular events as the outcome.
Description: This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.
Sponsorship: This study is sponsored solely by AstraZeneca through the provision of an unconditional educational grant.
URI: http://bmjopen.bmj.com/content/2/5/e001029
http://bura.brunel.ac.uk/handle/2438/7016
DOI: http://dx.doi.org/10.1136/bmjopen-2012-001029
ISSN: 2044-6055
Appears in Collections:Publications
Health Economics Research Group (HERG)

Files in This Item:

File Description SizeFormat
Fulltext.pdf404.11 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.